VCYT — Veracyte, Inc.

Summary of Veracyte, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $139.1 million, a 21% year-over-year increase.
• Testing Revenue: $135.1 million, up 26% year-over-year, driven by Decipher and Afirma growth of 30% and 21%, respectively.
• Total Volume: Approximately 47,600 tests, a 17% increase compared to Q1 2025.
• Adjusted EBITDA: $42.8 million, representing 30.8% of revenue, up 73% year-over-year.
• Cash Position: Ended the quarter with $439.1 million in cash, cash equivalents, and short-term investments.
• ASP: Increased to $2,980, up 6% year-over-year; normalized ASP (excluding prior-period collections) increased by 3% to $2,900.

2. Strategic Updates and Business Highlights

• Decipher Performance: Continued strong growth with approximately 28,000 tests delivered, reflecting 24% year-over-year volume growth, particularly in advanced disease categories.
• Afirma Transition: Successfully transitioned to the V2 transcriptome workflow, improving the no-result rate and contributing significantly to volume growth.
• Upcoming Product Launches:
  • Prosigna LDT: Set to launch mid-year, supported by the OPTIMA trial results presentation at ASCO in June.
  • TruMRD: Expected to launch by the end of Q2, focusing on muscle-invasive bladder cancer.
• Pipeline Expansion: Ongoing studies and trials aimed at enhancing clinical evidence for Decipher and Afirma, with a focus on integrating additional predictive biomarkers.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year total revenue guidance to $582 million - $592 million, reflecting 13% to 14% year-over-year growth.
• Testing Revenue Growth: Expected growth of 16% to 18%, with Decipher revenue projected to grow approximately 20% and Afirma in the high single-digit to low double-digit range.
• Adjusted EBITDA Guidance: Increased to greater than 26%, indicating confidence in profitability amidst ongoing investments.

4. Bad News, Challenges, or Points of Concern

• Seasonal Impact: Weather conditions in Q1 were slightly worse than the previous year, but the impact was managed within expectations.
• No-Result Rate: While improvements were noted, the company expects a potential decline in no-result rates during summer months due to RNA degradation.
• Competitive Pressures: The market for Decipher faces competition from newer, potentially lower-cost pathology and AI-based competitors, although Veracyte maintains a strong evidence base.

5. Notable Q&A Insights

• Decipher's Growth Sustainability: Management expressed confidence in sustaining growth due to the low penetration rate of Decipher among prostate cancer patients and ongoing clinical evidence supporting its use.
• Prosigna Launch Strategy: The launch will focus on demonstrating clinical superiority rather than solely competing on price, given the well-penetrated market.
• TruMRD's Market Potential: The platform is expected to address significant unmet needs in minimal residual disease monitoring, with plans for expansion into other cancer types based on ongoing studies.
• Capital Allocation Strategy: Veracyte remains open to M&A opportunities that align with its oncology-focused strategy, emphasizing the importance of maintaining strong financial health and avoiding dilutive acquisitions.

This summary encapsulates the key financial performance, strategic initiatives, future outlook, and challenges faced by Veracyte, Inc. in Q1 2026, providing a balanced view of the company's current standing and future prospects.